LONDON — The UK announced £3 million in new operational research funding for neglected tropical diseases (NTDs) at a parliamentary reception co-hosted by the UK Coalition Against NTDs and the All-Party Parliamentary Group on Malaria and NTDs, with ministers and lawmakers using the event to argue that Britain should restore its global leadership in the field. The pledge is modest beside earlier British programmes, but it gives Westminster a concrete answer to long-running criticism that UK support had become harder to read after aid cuts, Feb. 4, 2026.
At the reception, Baroness Chapman said the work must be “African-owned, African-led, and African delivered.” Organisers said the new money will support operational research on female genital schistosomiasis, migrant health and the integration of NTD services into stronger health systems.
That political message was followed by formal confirmation. In a written answer published Feb. 17, the Foreign, Commonwealth and Development Office said the UK will provide £3 million to the Coalition for Operational Research on NTDs for female genital schistosomiasis research and up to £15 million for the Eliminating Lymphatic Filariasis in Africa programme.
Why neglected tropical diseases are back on Westminster’s agenda
The timing is not accidental. WHO says more than 1 billion people are affected by NTDs, 58 countries have eliminated at least one, and official development assistance for NTDs fell 41% between 2018 and 2023. That combination explains the urgency now visible in Westminster: the case for action looks stronger, but the financing base is weaker.
For MPs and advocates, NTDs cut across several priorities at once. They are diseases of poverty, but they are also tied to girls’ health, disability, school attendance, migration, productivity and climate pressure. That makes them a sharper test of whether the UK wants to fund narrow interventions or back broader health-system reach.
Neglected tropical diseases and the UK’s unfinished record
The language of restoration matters because Britain has been here before. The UK helped launch the London Declaration on NTDs in 2012, one of the defining efforts to align governments, drugmakers and donors behind control and elimination goals.
It leaned further into that role in 2019, when ministers unveiled a £220 million package promising 600 million treatments and protection for 200 million people across 25 countries.
That trajectory broke sharply in 2021, when the early closure of ASCEND after aid cuts prompted warnings that missed treatments, lost training and interrupted community delivery could slow elimination and allow preventable disability to return.
By the start of 2024, the issue was already back in Westminster Hall, where MPs debated whether the UK was still matching its rhetoric on malaria and NTDs with credible, predictable support.
What the £3 million boost changes — and what it does not
By itself, £3 million will not recreate the scale of previous UK-backed delivery drives. What it does change is the signal. It tells researchers, implementers and endemic-country partners that NTDs have not entirely slipped off the British development map, and that Parliament still sees the field as a place where the UK can combine diplomacy, science and practical delivery.
That signal matters most in areas that have often fallen between policy silos. Female genital schistosomiasis, one of the priorities linked to the new funding, has long sat between disease control, women’s health and stigma, making it easy for fragmented systems and fragmented donors alike to miss.
If ministers want this announcement to look like the start of a reset rather than a one-off gesture, the next steps are straightforward: make funding predictable, keep it aligned with country-led delivery, and show that NTDs are part of the UK’s wider health offer rather than a niche add-on.
For now, Westminster has moved from rhetoric to a first concrete step. The real test is whether this £3 million boost becomes the opening bid in a broader British return to neglected tropical diseases, or simply a welcome but isolated moment.
